Coeptis Therapeutics Leverages Artificial Intelligence and Blockchain for Next-Generation Innovation

$COEP
Biotechnology: Biological Products (No Diagnostic Substances)
Health Care
Get the next $COEP alert in real time by email

Coeptis Harnesses AI Advances and Blockchain Initiatives to Drive Operational Efficiency and Strategic Growth

WEXFORD, Pa., Jan. 23, 2025 /PRNewswire/ -- Coeptis Therapeutics Holdings, Inc. (NASDAQ:COEP) (the "Company" or "Coeptis"), a biopharmaceutical company focused on pioneering cell therapy platforms for cancer, autoimmune, and infectious diseases, is excited to announce the expansion of its technological initiatives to include cutting-edge artificial intelligence and innovative blockchain solutions.

Following the successful launch of its Technology Division and the introduction of transformative AI capabilities, Coeptis has demonstrated significant promise in enhancing operational efficiency and customer engagement. The Company recognizes the enormous potential for AI to revolutionize the pharmaceutical landscape while exploring the opportunities provided by blockchain technology.

Dave Mehalick, President and CEO of Coeptis, stated, "We are thrilled to build upon the momentum we've generated with our Technology Division, particularly in the area of artificial intelligence, as we look to advance our initiatives leveraging blockchain technology. This expansion signifies not only our commitment to remaining at the forefront of technological developments but also our dedication to exploring new avenues that align with the rapidly evolving digital marketplace."

"The integration of blockchain initiatives into the Technology Division's portfolio reflects Coeptis's mission to adapt to emerging trends and leverage new market opportunities for enhanced value creation," added Mr. Mehalick. As we embark on this new journey, we are confident in our ability to drive innovation and explore synergies that will benefit our customers and shareholders.

About Coeptis Therapeutics Holdings, Inc.

Coeptis Therapeutics Holdings, Inc., together with its subsidiaries including Coeptis Therapeutics, Inc., Coeptis Pharmaceuticals, Inc., GEAR Therapeutics, Inc., and SNAP Biosciences, Inc. (collectively "Coeptis"), is a biopharmaceutical and technology company focused on developing innovative cell therapy platforms for cancer, autoimmune, and infectious diseases. Coeptis aims to advance treatment paradigms and improve patient outcomes through its cutting-edge research and development efforts.

The Company's therapeutic portfolio is underscored by assets licensed from Deverra Therapeutics, which include an allogeneic cellular immunotherapy platform and DVX201, a clinical-stage, unmodified natural killer cell therapy technology. Coeptis is also developing a universal, multi-antigen CAR technology licensed from the University of Pittsburgh (SNAP-CAR), alongside GEAR cell therapy and companion diagnostic platforms in collaboration with VyGen-Bio and distinguished medical researchers at the Karolinska Institute.

Building on its core competencies, Coeptis has recently established a Technology Division, which focuses on enhancing operational capabilities through advanced technologies. This division features AI-powered marketing software and robotic process automation tools acquired from NexGenAI Solutions Group, designed to optimize business processes and improve overall efficiency.

Headquartered in Wexford, PA, Coeptis is dedicated to advancing its mission within the regulatory framework set forth by the FDA, ensuring that all activities align with the highest standards of compliance and patient care. For more information on Coeptis, visit https://coeptistx.com

Cautionary Note Regarding Forward-Looking Statements

This press release and statements of our management made in connection therewith contain or may contain "forward-looking statements" (as defined in Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended). Forward-looking statements include statements concerning our plans, objectives, goals, strategies, future events or performance, and underlying assumptions, and other statements that are other than statements of historical facts. When we use words such as "may," "will," "intend," "should," "believe," "expect," "anticipate," "project," "estimate" or similar expressions that do not relate solely to historical matters, we are making forward-looking statements. Forward-looking statements are not a guarantee of future performance and involve significant risks and uncertainties that may cause the actual results to differ materially and perhaps substantially from our expectations discussed in the forward-looking statements. Factors that may cause such differences include but are not limited to: (1) the inability to maintain the listing of the Company's securities on the Nasdaq Capital Market; (2) the inability to recognize the anticipated benefits of the Deverra licensed assets, which may be affected by, among other things, competition, the ability of the Company to grow and manage growth economically and hire and retain key employees; (3) the risks that the Company's products in development or the newly-licensed assets fail clinical trials or are not approved by the U.S. Food and Drug Administration or other applicable regulatory authorities; (4) costs related to ongoing asset development including the Deverra licensed assets and pursuing the contemplated asset development paths; (5) changes in applicable laws or regulations; (6) the possibility that the Company may be adversely affected by other economic, business, and/or competitive factors; and (7) the impact of the global COVID-19 pandemic on any of the foregoing risks and other risks and uncertainties identified in the Company's filings with the Securities and Exchange Commission (the "SEC"). The foregoing list of factors is not exclusive. All forward-looking statements are subject to significant uncertainties and risks including, but not limited, to those risks contained or to be contained in reports and other filings filed by the Company with the SEC. For these reasons, among others, investors are cautioned not to place undue reliance upon any forward-looking statements in this press release. Additional factors are discussed in the Company's filings made or to be made with the SEC, which are available for review at www.sec.gov. We undertake no obligation to publicly revise these forward-looking statements to reflect events or circumstances that arise after the date hereof unless required by applicable laws, regulations, or rules.

Contacts

IR@coeptistx.com

Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/coeptis-therapeutics-leverages-artificial-intelligence-and-blockchain-for-next-generation-innovation-302358118.html

SOURCE Coeptis Pharmaceuticals, Inc.

Get the next $COEP alert in real time by email

Chat with this insight

Save time and jump to the most important pieces.

Recent Analyst Ratings for
$COEP

DatePrice TargetRatingAnalyst
More analyst ratings

$COEP
Press Releases

Fastest customizable press release news feed in the world

See more
  • Coeptis Therapeutics Secures Worldwide Development and Commercialization Rights to Next-Generation GEAR™ Cell Therapy Platform Strengthening its High-Impact Precision Immuno-Oncology Pipeline

    • COEP forms GEAR Therapeutics, as a majority-owned subsidiary, to advance GEAR-modified natural killer (NK) cells into first-in-human studies for broad range of cancers and other therapeutic modalities. WEXFORD, Pa., March 11, 2025 (GLOBE NEWSWIRE) -- COEPTIS, Inc. (NASDAQ:COEP) ("the Company" or "Coeptis"), a pioneering technology firm at the forefront of innovative biotechnology solutions today announced it has successfully licensed exclusive worldwide development and commercialization rights to the GEAR™ (Gene Edited Antibody Resistant) Cell Therapy Platform, representing a first-in-class approach to modifying potent cancer-targeting immune cells to optimize the likelihood of deep r

    $COEP
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
  • COEPTIS' NexGenAI Affiliates Partners with NUBURU Network to Drive Innovation in AI and Robotics as Part of its Transformation Plan

    WEXFORD, Pa., March 07, 2025 (GLOBE NEWSWIRE) -- COEPTIS, Inc. (NASDAQ:COEP) ("the Company" or "COEPTIS"), a pioneering technology firm at the forefront of innovative biotechnology solutions today announced its strategic partnership with COEPTIS' NexGenAI Affiliates Network "NexGen" and NUBURU, Inc. "NUBURU" (NYSE:BURU), a leading innovator in high-power blue laser technology. This collaboration is a pivotal component of COEPTIS' strategic position in technology and Artificial Intelligence and NUBURU's comprehensive Transformation Plan, spearheaded by Executive Chairman Alessandro Zamboni, aimed at enhancing operational efficiency and revamping the company's business model entering defense

    $BURU
    $COEP
    Industrial Machinery/Components
    Miscellaneous
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
  • NUBURU Partners With COEPTIS NexGenAI Affiliates Network to Drive Innovation in AI and Robotics as Part of Its Transformation Plan

    NUBURU, Inc. (NYSE:BURU), a leading innovator in high-power and high-brightness industrial blue laser technology announced its strategic partnership with COEPTIS' NexGenAI Affiliates Network (NASDAQ:COEP), an innovative provider of artificial intelligence and robotics solutions. This collaboration is a pivotal component of NUBURU's comprehensive Transformation Plan, spearheaded by Executive Chairman Alessandro Zamboni, aimed at enhancing operational efficiency and revamping the company's business model. The Transformation Plan, by leveraging the existing know-how regarding blue-laser technology and additional expertise to be brought by the new management team, is specifically designed to l

    $BURU
    $COEP
    Industrial Machinery/Components
    Miscellaneous
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

$COEP
Insider Trading

Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

See more

$COEP
SEC Filings

See more

$COEP
Leadership Updates

Live Leadership Updates

See more
  • Coeptis Therapeutics Appoints Colleen Delaney, MD, as Chief Scientific and Medical Officer

    Dr. Delaney joins Coeptis after securing exclusive rights from Deverra Therapeutics for its allogeneic immuno-oncology platform and clinical stage programs WEXFORD, Pa., Aug. 30, 2023 /PRNewswire/ -- Coeptis Therapeutics Holdings, Inc. (NASDAQ:COEP) ("Coeptis" or "the Company"), a biopharmaceutical company developing innovative cell therapy platforms for cancer, announced that Colleen Delaney, MD, MSc, has been appointed Chief Scientific and Medical Officer of Coeptis following the completion of an exclusive rights agreement with Deverra Therapeutics for its allogeneic immuno-oncology platform and clinical stage programs.

    $COEP
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
  • Coeptis Therapeutics Appoints Brian Cogley as Chief Financial Officer

    15-year accounting and finance career spans several sectors including life sciences and underscores financial leadership abilities WEXFORD, Pa., May 17, 2023 /PRNewswire/ -- Coeptis Therapeutics Holdings, Inc. (NASDAQ:COEP) ("Coeptis" or the "Company"), a biopharmaceutical company developing innovative cell therapy platforms for cancer, announced today the appointment of Brian Cogley, MBA, to the position of Chief Financial Officer (CFO) effective immediately. Mr. Cogley brings 15 years of accounting and finance experience to Coeptis, having previously held positions of increasing authority at two "Big 4" accounting firms and served on the management teams of multiple companies in diverse in

    $COEP
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

$COEP
Financials

Live finance-specific insights

See more
  • Coeptis Therapeutics Completes Exclusive License for Allogeneic Immuno-Oncology Platform and Clinical Stage Assets from Deverra Therapeutics

    Coeptis bolsters pipeline with two Phase 1 clinical stage assets leveraging NK cell therapies in relapsed or refractory acute myeloid leukemia (AML)/high risk MDS and hospitalized respiratory infections, as well as preclinical programs for hematologic and solid tumors WEXFORD, Pa., Aug. 17, 2023 /PRNewswire/ -- Coeptis Therapeutics Holdings, Inc. (NASDAQ:COEP) ("Coeptis" or "the Company"), a biopharmaceutical company developing innovative cell therapy platforms for cancer, announced that it has completed the exclusive license of key assets from Deverra Therapeutics Inc. ("Deverra") related to its proprietary allogeneic stem cell expansion and directed differentiation platform for the generat

    $COEP
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

$COEP
Large Ownership Changes

This live feed shows all institutional transactions in real time.

See more